arrow
L

Lucy Kilburn

University of London
H指数:31
被引数:7,275

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Baseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5 years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials

基线特征预测5年内缺失患者报告生活质量数据较低返报率:IMPORT HIGH和IMPORT LOW乳腺癌放疗试验的证据

2025-11-270
OAAI
Use of routinely collected health data (England) to identify subsequent disease-related events in patients with primary breast cancer: a practical alternative to hospital-based follow-up for breast cancer clinical trials

利用常规收集的健康数据(英格兰)识别原发性乳腺癌患者后续的疾病相关事件:作为乳腺癌临床试验中基于医院的随访的一种实用替代方案

2025-09-260
OAAI
Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial

IMPORT HIGH III期随机对照试验中接受追加剂量放疗的乳腺癌患者报告的五年不良反应趋势及基线预测因素

2025-07-230
OAAI
Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+/HER2+ early breast cancer: a POETIC translational study

短期术前内分泌治疗改变ER+/HER2+早期乳腺癌的分子谱以预测良好结局:一项POETIC转化研究

2025-07-180
OA
Genomic characterization of endocrine resistance in ER+HER2+breast cancers in the POETIC Trial
2024-05-020
PRE
The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial
2024-05-020
PRE
Tracking triple negative breast cancer (TNBC) evolution in the molecular residual disease (MRD) setting in the c-TRAK TN clinical trial
2024-03-220
PRE
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
2023-12-110
OAAI
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
2023-09-294
OAAI